December 22, 2022 – According to a report by PharmaNewsIntelligence, Pfizer is investing $750 million to expand its Kalamazoo, Mich., manufacturing facility to increase the production of its injectable medicines and vaccines. The expansion will allow Pfizer to increase production on vaccines and medicines using the same mRNA technology that is currently being used in the Pfizer-BioNTech COVID-19 vaccine.
“At Pfizer, we continue to invest in our manufacturing infrastructure, building a more resilient supply chain, so patients have the medicines and vaccines they need,” said Mike McDermott, Chief Global Supply Officer, Executive Vice President of Pfizer. “This latest investment in our Kalamazoo site will help us advance some of the most innovative manufacturing technologies in sterile injectable production and distribution while increasing access to these vital medicines.”
This specific location is one of Pfizer’s largest plants, specializing in active pharmaceutical ingredients, drug products, and medical devices. The expansion will likely create 300 long-term jobs, adding to the existing 3,000 jobs at the facility.